Third Harmonic Bio Inc. (THRD) - Net Assets
Based on the latest financial reports, Third Harmonic Bio Inc. (THRD) has net assets worth $272.62 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($279.84 Million) and total liabilities ($7.21 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read debt load of Third Harmonic Bio Inc. for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $272.62 Million |
| % of Total Assets | 97.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 6.44 |
Third Harmonic Bio Inc. - Net Assets Trend (2020–2024)
This chart illustrates how Third Harmonic Bio Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore THRD total asset value for the complete picture of this company's asset base.
Annual Net Assets for Third Harmonic Bio Inc. (2020–2024)
The table below shows the annual net assets of Third Harmonic Bio Inc. from 2020 to 2024. For live valuation and market cap data, see Third Harmonic Bio Inc. (THRD) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $285.15 Million | +5.97% |
| 2023-12-31 | $269.08 Million | -6.91% |
| 2022-12-31 | $289.07 Million | +718.91% |
| 2021-12-31 | $-46.71 Million | -154.43% |
| 2020-12-31 | $-18.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Third Harmonic Bio Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14105700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Components | $444.83 Million | 156.00% |
| Total Equity | $285.15 Million | 100.00% |
Third Harmonic Bio Inc. Competitors by Market Cap
The table below lists competitors of Third Harmonic Bio Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Becamex Infrastructure Development JSC
VN:IJC
|
$242.79 Million |
|
Escalade Incorporated
NASDAQ:ESCA
|
$242.81 Million |
|
AME Elite Consortium Bhd
KLSE:5293
|
$242.84 Million |
|
Zhejiang Heda Technology Co Ltd
SHG:688296
|
$242.99 Million |
|
LAVIPHARM S.A. NA EO 1
F:BXA0
|
$242.59 Million |
|
Shin Shin Natural Gas Co Ltd
TW:9918
|
$242.56 Million |
|
Sam Yung Tradi
KO:002810
|
$242.51 Million |
|
Vertical Aerospace Ltd
NYSE:EVTL
|
$242.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Third Harmonic Bio Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 269,085,000 to 285,150,000, a change of 16,065,000 (6.0%).
- Net income of 45,469,000 contributed positively to equity growth.
- New share issuances of 48,668,000 increased equity.
- Other factors decreased equity by 78,072,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $45.47 Million | +15.95% |
| Share Issuances | $48.67 Million | +17.07% |
| Other Changes | $-78.07 Million | -27.38% |
| Total Change | $- | 5.97% |
Book Value vs Market Value Analysis
This analysis compares Third Harmonic Bio Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.79x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 608.69x to 0.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.01 | $5.38 | x |
| 2021-12-31 | $3.19 | $5.38 | x |
| 2022-12-31 | $7.34 | $5.38 | x |
| 2023-12-31 | $6.79 | $5.38 | x |
| 2024-12-31 | $6.83 | $5.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Third Harmonic Bio Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.95%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (15.95%) is above the historical average (-755.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -3744.74% | 0.00% | 0.00x | 24.66x | $-12.84 Million |
| 2021 | -23.98% | 0.00% | 0.00x | 1.05x | $-41.96 Million |
| 2022 | -13.04% | 0.00% | 0.00x | 1.03x | $-66.61 Million |
| 2023 | -11.46% | 0.00% | 0.00x | 1.03x | $-57.73 Million |
| 2024 | 15.95% | 0.00% | 0.00x | 1.03x | $16.95 Million |
Industry Comparison
This section compares Third Harmonic Bio Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Third Harmonic Bio Inc. (THRD) | $272.62 Million | -3744.74% | 0.03x | $242.79 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Third Harmonic Bio Inc.
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibit… Read more